We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis

News   Sep 04, 2013

 
Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis
 
 
 

RELATED ARTICLES

Why Do Our Immune Responses Differ?

News

A study of 1,000 individuals has identified three main factors that determine how our immune responses differ. The research might help identify ways to make better vaccines and improve our understanding of autoimmune disease.

READ MORE

Breast Cancers Enlist the Help of Normal Cells to Help Them Spread & Survive

News

Researchers have shown that triple negative breast tumours - which are the most aggressive and have the fewest treatment options - might one day be treated with a drug that cuts the 'phone lines' between normal cells and tumour cells.

READ MORE

Hunt for the Missing T-Cells in Glioblastoma Patients

News

Glioblastoma brain tumors can have an unusual effect on the body’s immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body’s defenses.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE